SIMPONI to Arrest β-cell Loss in Type 1 Diabetes

Trial Profile

SIMPONI to Arrest β-cell Loss in Type 1 Diabetes

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms T1GER
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 11 Jul 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Feb 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2017 Planned End Date changed from 7 Oct 2019 to 25 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top